About this trial
Venous thromboembolic disease is a common pathology in the general population (1.5/1000), the prognosis of which depends in particular on the risk of recurrence. This risk depends essentially on whether the thrombotic episode was provoked or not. Thus, patients who present a thromboembolic event without any contributing factor have a high risk of recurrence, which encourages clinicians to continue anticoagulant treatment for a long time. However, anticoagulant treatment is the leading cause of hospitalization for iatrogenic causes and the leading cause of iatrogenic mortality. The benefit-risk balance of treatment must be evaluated regularly, which requires a good knowledge of the risk factors for thrombotic recurrence and the risk factors for hemorrhage.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Deep vein thrombosis confirmed by Doppler ultrasound or CT venography,
Pulmonary embolism confirmed by CT angiography, ventilation/perfusion scan, or confirmed DVT episode with respiratory signs consistent with PE.
Hospitalization in the Internal Medicine Department
Consultation by an Internal Medicine physician
Disqualifiers
None
Trial population
Patient having experienced at least one venous thromboembolic episode
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Rate of recurrence in patients treated with venous thromboembolic disease (VTE)
Evaluation of the number of hospitalizations or consultations for a venous thrombotic recurrence
Rate of bleeding complications in patients treated with venous thromboembolic disease (VTE)
Evaluation of the number of hospitalizations or consultations for a hemorrhagic complication.
Secondary outcomes
Long-term complication rates
Assessment of the occurrence of long-term complications
Long-term complication rates
Assessment of mortality
Sponsors and contacts
Click on the lead sponsor to view all of their trials.